R&D Pipeline
Nektar Therapeutics has a deep and diverse portfolio of investigational medicines in different stages of clinical development. We are focused on using new chemistry approaches to make better medicines to treat cancer and auto-immune disease.
Nektar Therapeutics also has a number of strategic partnerships ranging from joint discovery and co-development to licensing and royalty arrangements with numerous companies.
ONZEALD® (etirinotecan pegol)
Indication: Advanced breast cancer and brain metastases
Discovered and wholly owned by Nektar
Unpartnered
More InfoBempegaldesleukin (NKTR-214) in combination with OPDIVO® (nivolumab)
Indication: Melanoma
Partner
Bempegaldesleukin in combination with OPDIVO® (nivolumab)
Indication: Renal Cell Carcinoma
Partner
Bempegaldesleukin in combination with OPDIVO® (nivolumab)
Indication: Muscle-invasive Bladder Cancer
Partner
Bempegaldesleukin in combination with OPDIVO® (nivolumab)
Indication: Urothelial Cancer*
Partner
Bempegaldesleukin in combination with OPDIVO® (nivolumab)
Research Focus: Immuno-oncology
Discovered by Nektar
In clinical collaboration with
Dapirolizumab Pegol (Anti-CD40L)
Indication: Systemic lupus erythematosus (SLE)
Partner
In partnership with
Systemic lupus erythematosus (SLE) is a chronic inflammatory disease that occurs when the body's own immune system mistakenly attacks healthy tissue in skin, joints, kidneys, the brain and other organs. It is a difficult disease to diagnose because it resembles several other conditions.
CD40L is a protein in B and T cells, which helps regulate the immune system. Dapirolizumab pegol (Anti-CD40L) is an antibody that blocks CD40L, potentially lessening disease activity in SLE patients. Dapirolizumab pegol is being developed by Biogen and UCB, Inc. in a Phase 2 clinical trial to evaluate the efficacy and safety of dapirolizumab pegol in patients with moderately to severely active systemic lupus erythematosus. For more information about this study, visit clinicaltrials.gov.
Bempegaldesleukin in combination with VB10.NEO
Indication: Squamous Cell Carcinoma of the Head and Neck
In clinical collaboration with
Bempegaldesleukin in combination with avelumab
Indication: Squamous Cell Carcinoma of the Head and Neck
In clinical collaboration with
Bempegaldesleukin in combination with avelumab and talazaparib or enzalutamide
Indication: Metastatic Castration-resistant Prostate Cancer
In clinical collaboration with
Bempegaldesleukin in combination with KEYTRUDA® (pembrolizumab)
Indication: Select Advanced or Metastatic Solid Tumors
Discovered and wholly owned by Nektar
Unpartnered
More InfoNKTR-262 in combination with bempegaldesleukin
INDICATION: Locally Advanced or Metastatic Solid Tumor Malignancies
Discovered and wholly owned by Nektar
Unpartnered
More InfoNKTR-255
INDICATION: Hematological Malignancies
Discovered and wholly owned by Nektar
Unpartnered
More InfoLess InfoNKTR-255 is a memory T cell stimulating cytokine designed to engage the IL-15 pathway to enhance and sustain long-term T cell memory response to treat cancer.
*Planned registrational study
ONZEALD is a registered trademark of Nektar Therapeutics, OPDIVO® is a registered trademark of Bristol-Myers Squibb; KEYTRUDA is a registered trademark of Merck & Co., Inc.
